{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:52:33Z","timestamp":1782121953505,"version":"3.54.5"},"reference-count":36,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Respiratory Infections, Imperial College London","award":["NIHR200927"],"award-info":[{"award-number":["NIHR200927"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 13600061"],"award-info":[{"award-number":["WT 13600061"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Respiratory Syncytial Virus Consortium in Europe","award":["116019"],"award-info":[{"award-number":["116019"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2026,1,25]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation due to lower respiratory tract infections. Until 2022, prevention was limited to the costly monoclonal antibody palivizumab. In August 2024, the UK introduced the RSVpreF (Abrysvo, Pfizer) maternal vaccine into its national immunisation schedule. The success of this programme depends not only on vaccine effectiveness, but also on maternal access, acceptance and uptake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore maternal perspectives on the RSVpreF vaccine and identify barriers and facilitators to vaccine uptake, to inform antenatal education and public health strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This qualitative analysis is based on free-text survey responses from 388 vaccine-eligible mothers of infants hospitalised with bronchiolitis, lower respiratory tract infection or acute wheeze, collected between September 2024 and March 2025 across 30 sites, as part of the BronchStop study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four key themes were identified: (1) access-related barriers to vaccination, (2) insufficient RSV awareness and information to support informed decision-making, (3) vaccine safety concerns and hesitancy and (4) perception of the maternal RSV vaccine as beneficial and protective. These themes were consistent across sociodemographic groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Uptake of the maternal vaccine was influenced by barriers to access, informational gaps and perceived safety concerns. Improved vaccine delivery, enhanced awareness and personalised antenatal counselling are essential to increase vaccine uptake. There is an urgent need to address structural inaccessibility and provide tailored antenatal education to address informational gaps. Ongoing qualitative research is crucial to guide targeted public health interventions ahead of future RSV seasons.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/archdischild-2025-329427","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:20:13Z","timestamp":1772043613000},"page":"618-624","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland"],"prefix":"10.1136","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-4202","authenticated-orcid":false,"given":"Shaun","family":"O\u2019Hagan","sequence":"first","affiliation":[{"name":"Wellcome Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C","family":"Williams","sequence":"additional","affiliation":[{"name":"Child Life and Health, University of Edinburgh Division of Clinical and Surgical Sciences, Edinburgh, UK"},{"name":"Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-3102","authenticated-orcid":false,"given":"Robin","family":"Marlow","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, UK"},{"name":"Emergency Department, Bristol Royal Hospital for Children, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-6557","authenticated-orcid":false,"given":"Simon B","family":"Drysdale","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"},{"name":"NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7342-251X","authenticated-orcid":false,"given":"Steve","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK"},{"name":"The University of Edinburgh Centre for Inflammation Research, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-9961","authenticated-orcid":false,"given":"Helen Elizabeth","family":"Groves","sequence":"additional","affiliation":[{"name":"Wellcome Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK"},{"name":"Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengetai D","family":"Mpamhanga","sequence":"additional","affiliation":[{"name":"Child Life and Health, University of Edinburgh Division of Clinical and Surgical Sciences, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-7210","authenticated-orcid":false,"given":"Mark D","family":"Lyttle","sequence":"additional","affiliation":[{"name":"Emergency Department, Bristol Royal Hospital for Children, Bristol, UK"},{"name":"Research in Emergency Care Avon Collaborative Hub (REACH), University of the West of England, Bristol, UK"},{"name":"Emergency Department, Perth Children's Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Hunt","sequence":"additional","affiliation":[{"name":"Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, University Hospitals of Leicester NHS Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxue","family":"Liu","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Waterfield","sequence":"additional","affiliation":[{"name":"Wellcome Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9334-5144","authenticated-orcid":false,"given":"Damian","family":"Roland","sequence":"additional","affiliation":[{"name":"Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, University Hospitals of Leicester NHS Trust, Leicester, UK"},{"name":"Population Health Sciences, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Iskander","sequence":"additional","affiliation":[{"name":"Department of Anthropology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5726-5304","authenticated-orcid":false,"given":"Kerry","family":"Woolfall","sequence":"additional","affiliation":[{"name":"Public Health, Policy and Systems, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026062202301068000_111.7.618.1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004016"},{"key":"2026062202301068000_111.7.618.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00478-0"},{"key":"2026062202301068000_111.7.618.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009337","article-title":"Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK","volume":"6","author":"Taylor","year":"2016","journal-title":"BMJ Open"},{"key":"2026062202301068000_111.7.618.4","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1093\/infdis\/jiad551","article-title":"Clinical Impact of Serious Respiratory Disease in Children Under the Age of 2 Years During the 2021\u20132022 Bronchiolitis Season in England, Scotland, and Ireland","volume":"230","author":"Williams","year":"2024","journal-title":"J Infect Dis"},{"key":"2026062202301068000_111.7.618.5","unstructured":"Fusco F , Hocking L , Stockwell S , et al . The burden of respiratory syncytial virus: understanding impacts on the NHS, society and economy. Santa Monica, CA: RAND Corporation PP, 2022."},{"key":"2026062202301068000_111.7.618.6","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S348727"},{"key":"2026062202301068000_111.7.618.7","unstructured":"Royal College of Physicians of Ireland, National Immunisation Advisory Committee . Recommendations for passive immunisation and vaccination against respiratory syncytial virus in infants, children and older adults. 2023."},{"key":"2026062202301068000_111.7.618.8","doi-asserted-by":"crossref","unstructured":"Phillips B , Jackson C , Phillips J . Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants. J Pharm Technol 2025.:87551225251392119. doi:10.1177\/87551225251392119","DOI":"10.1177\/87551225251392119"},{"key":"2026062202301068000_111.7.618.9","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2026062202301068000_111.7.618.10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2216480"},{"key":"2026062202301068000_111.7.618.11","unstructured":"GOV.UK . Respiratory syncytial virus (rsv) vaccination programme [internet]. 2024. Available: https:\/\/www.gov.uk\/government\/collections\/respiratory-syncytial-virus-rsv-vaccination-programme"},{"key":"2026062202301068000_111.7.618.12","unstructured":"GBD, Vaccine Coverage Collaborators . Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 2025;01037\u20132."},{"key":"2026062202301068000_111.7.618.13","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000002384"},{"key":"2026062202301068000_111.7.618.14","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/INF.0000000000004632","article-title":"Protecting Against Respiratory Syncytial Virus: An Online Questionnaire Study Exploring UK Parents\u2019 Acceptability of Vaccination in Pregnancy or Monoclonal Antibody Administration for Infants","volume":"44","author":"Paulson","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2026062202301068000_111.7.618.15","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41562-022-01431-6","article-title":"A systematic literature review to clarify the concept of vaccine hesitancy","volume":"6","author":"Bussink-Voorend","year":"2022","journal-title":"Nat Hum Behav"},{"key":"2026062202301068000_111.7.618.16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41562-022-01484-7","article-title":"Defining and measuring vaccine hesitancy","volume":"6","author":"Larson","year":"2022","journal-title":"Nat Hum Behav"},{"key":"2026062202301068000_111.7.618.17","unstructured":"Royal College of Paediatrics and Child Health (RCPCH) . Policy report: vaccination in the UK\u2014access, uptake and equity. RCPCH Commission on Immunisation; 2024\u201325. Available: https:\/\/www.rcpch.ac.uk\/sites\/default\/files\/2025-06\/Vaccination-in-UK-access-uptake-equity_policy-report-2025.pdf"},{"key":"2026062202301068000_111.7.618.18","unstructured":"GOV UK . RSV maternal vaccination coverage in England. 2025. Available: https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-for-older-adults-and-pregnant-women-vaccine-coverage-in-england\/rsv-maternal-vaccination-coverage-in-england-february-2025"},{"key":"2026062202301068000_111.7.618.19","unstructured":"GOV.UK . Prenatal pertussis vaccination coverage in England from January to March 2025, and annual coverage for 2024 to 2025. 2025. Available: https:\/\/www.gov.uk\/government\/publications\/pertussis-immunisation-in-pregnancy-vaccine-coverage-estimates-in-england-october-2013-to-march-2014\/prenatal-pertussis-vaccination-coverage-in-england-from-january-to-march-2025-and-annual-coverage-for-2024-to-2025"},{"key":"2026062202301068000_111.7.618.20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.12688\/wellcomeopenres.16778.3","article-title":"Update to: Study Pre-protocol for \u201cBronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study\u201d","volume":"6","author":"Williams","year":"2024","journal-title":"Wellcome Open Res"},{"key":"2026062202301068000_111.7.618.21","unstructured":"Patient information leaflet: the patient information leaflet is available online as part of the extended data for the bronchstop study protocol. n.d. Available: https:\/\/era.ed.ac.uk\/handle\/1842\/37604"},{"key":"2026062202301068000_111.7.618.22","unstructured":"Consent form: the consent form is available online as part of the extended data for the bronchstop study protocol. n.d. Available: https:\/\/era.ed.ac.uk\/handle\/1842\/37604"},{"key":"2026062202301068000_111.7.618.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208601","article-title":"Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination","volume":"13","author":"Betsch","year":"2018","journal-title":"PLoS ONE"},{"key":"2026062202301068000_111.7.618.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2026062202301068000_111.7.618.25","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1473-3099(25)00060-X","article-title":"Maternal views on RSV vaccination during the first season of implementation in England and Scotland","volume":"25","author":"Williams","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026062202301068000_111.7.618.26","unstructured":"Maternal survey: the maternal survey is available online as part of the extended data for the bronchstop study protocol. n.d. Available: https:\/\/era.ed.ac.uk\/handle\/1842\/37604"},{"key":"2026062202301068000_111.7.618.27","unstructured":"Clarke V , Braun V . Teaching thematic analysis: overcoming challenges and developing strategies for effective learning. Psychologist;26:120\u20133."},{"key":"2026062202301068000_111.7.618.28","unstructured":"Lumivero . NVivo (version 14) [computer software]. 2023. Available: https:\/\/lumivero.com\/products\/nivo"},{"key":"2026062202301068000_111.7.618.29","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2341505","article-title":"Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody","volume":"20","author":"Treston","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026062202301068000_111.7.618.30","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1007\/s10995-022-03508-0","article-title":"Understanding Barriers and Facilitators to Maternal Immunization: A Systematic Narrative Synthesis of the Published Literature","volume":"26","author":"Geoghegan","year":"2022","journal-title":"Matern Child Health J"},{"key":"2026062202301068000_111.7.618.31","unstructured":"UK . Latest figures show strong uptake of whooping cough vaccine in pregnancy [internet]. 2025. Available: https:\/\/www.gov.uk\/government\/news\/latest-figures-show-strong-uptake-of-whooping-cough-vaccine-in-pregnancy"},{"key":"2026062202301068000_111.7.618.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103281","article-title":"Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis","volume":"84","author":"Trusinska","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026062202301068000_111.7.618.33","doi-asserted-by":"publisher","DOI":"10.1111\/apa.17168"},{"key":"2026062202301068000_111.7.618.34","unstructured":"Office for National Statistics (ONS) . Ethnic group, England and Wales. [internet]. 2022. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/culturalidentity\/ethnicity\/bulletins\/ethnicgroupenglandandwales\/census2021"},{"key":"2026062202301068000_111.7.618.35","unstructured":"Raleigh V . The health of people from ethnic minority groups in England. [internet]. The King\u2019s Fund, 2023. Available: https:\/\/www.kingsfund.org.uk\/insight-and-analysis\/long-reads\/health-people-ethnic-minority-groups-england"},{"key":"2026062202301068000_111.7.618.36","unstructured":"GOV.UK . RSV maternal vaccination coverage in England [Internet]. 2025. Available: https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-for-older-adults-and-pregnant-women-vaccine-coverage-in-england\/rsv-maternal-vaccination-coverage-in-england-september-2024"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2025-329427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:36:49Z","timestamp":1782121009000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2025-329427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/archdischild-2025-329427"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2025-329427","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}